StemCell Therapy

Advances in the stem cell therapy sector have been phenomenal over the years. Its assistance in curing humans of various diseases and disorders has generated expansive advancements. These advancements are not just limited to humans. Stem cell therapy has also acquired a prominent place in the veterinary sector.

The influence of animal stem cell therapy for the treatment of various animals for diverse diseases and disorders is growing rapidly. Therefore, this factor may help the global animal stem cell therapy market to generate exponential growth across the forecast period of 2019-2029. Stem cells help in the replacement of neurons affected by stroke, Parkinsons disease, spinal cord injury, Alzheimers disease, and others.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6816

This animal stem cell therapy market report has extensive information on various aspects associated with bringing growth. Important factors such as emerging trends, mergers and acquisitions, and the regional scenario of the animal stem cell therapy market have been analyzed and included in the report. The stakeholders can derive a treasure of information from this report. This report also includes a scrutinized take on the COVID-19 impact on the animal stem cell therapy market.

Animal Stem Cell Therapy Market: Competitive Prospects

The competitive landscape of the animal stem cell therapy market can be described as mildly fragmented. With a considerable chunk of players, the animal stem cell therapy market is surrounded by substantial competition. Research and development activities form an important part of the growth landscape because they help gain novel insights.

Activities such as mergers, acquisitions, joint ventures, collaborations, and partnerships form the foundation of the growth of the animal stem cell therapy market. These activities help manufacturers to gain influence and eventually help in increasing the growth rate of the animal stem cell therapy market. Prominent participants in the animal stem cell therapy market are Magellan Stem Cells, Medivet Biologics LLC, Kintaro Cells Power, U.S. Stem Cell, Inc., Celavet Inc., VETSTEM BIOPHARMA, and VetCell Therapeutics.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=6816&ltype=S

Animal Stem Cell Therapy Market: Key Trends

Infections are scaling up among animals at a rapid rate. The alarming increase is proving fatal for many animals. Therefore, to avoid such incidences and treat existing diseases and disorders, animal stem cell therapy is being applied seamlessly. Hence, this aspect may bring great growth opportunities for the animal stem cell therapy market.

Developments have been observed across the animal stem cell therapy market for long. Autologous adipose-derived mesenchymal stem cells are gaining traction for successfully resolving a range of issues in animals. These stem cells help in treating ligament and tendon injuries to a certain extent. The strengthening influence of this stem cell type in companion animals is also proving to be a prominent growth prospect for the animal stem cell therapy market.

Recent research has also found that stem cell-derived CC exosomes showed improved recovery from myocardial infarction (MI) among pigs. Such developments assure promising growth for the animal stem cell therapy market.

Animal Stem Cell Therapy Market: Regional Analysis

The animal stem cell therapy market is spread across North America, Latin America, the Middle East and Africa, Europe, and Asia Pacific. The animal stem cell therapy market may derive significant growth from North America. The escalating awareness regarding animal stem cell therapy may attract profound growth. Strengthening research and development activities in the region regarding animal stem cell therapy is further expanding the growth prospects.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6816

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Read more from the original source:
Animal Stem Cell Therapy Market - Great Growth Opportunities for the Market in the Coming Year | TMR Research Study - BioSpace

The FDA has issued (PDF) a complete response letter to Mesoblasts request for approval of allogeneic cell therapy remestemcel-L in children with steroid-resistant graft-versus-host disease. FDA officials want to see data from at least one additional clinical trial before granting full authorization, but Mesoblast is still hoping to snag an accelerated approval using its existing data.

Evidence of the FDAs concerns with Mesoblasts remestemcel-L filing emerged in August when the agency released a briefing document to inform a discussion of the application by the Oncologic Drugs Advisory Committee (ODAC). The FDA cited multiple perceived shortcomings of the filing, arguing for example that the ability of the mesenchymal stem cell therapy to reduce inflammation as measured by inflammatory biomarkers in humans receiving the product has not been demonstrated.

Despite the FDAs concerns, ODAC members voted nine to one that the data support the efficacy of remestemcel-L in children with steroid-resistant graft-versus-host disease. The positive ODAC vote sent shares in Mesoblast, which had been depressed by the briefing document, up 50%.

Inside the COVID-SeroIndex Assay Design and Performance

Join a panel of experts as they discuss the rigor involved in optimizing and scaling a reproducible serological assay for COVID-19.

However, the ODAC vote was advisory, and the FDA, in a rare but far from unprecedented action, has chosen to go against the recommendation of the committee. Shares in Mesoblast fell 37% in response to the rejection, sinking back to the low they hit in the wake of the briefing document.

Mesoblast said the FDA has recommended it runs at least one additional randomized clinical trial in adults or children with steroid-resistant graft-versus-host disease before refiling for approval. The recommendation suggests Mesoblast will need to expend time and money to get remestemcel-L to market. The phase 3 trial cited in the briefing document lasted almost three years.

However, Mesoblast is holding out hope that it can get remestemcel-L to some patients without the extra data requested by the FDA. In light of the unmet medical need, Mesoblast plans to request a Type A meeting with FDA to discuss the possibility of an accelerated approval. Mesoblast is hoping the FDA will agree to authorize remestemcel-L on the proviso that it runs a study post-approval.

If Mesoblast is to persuade the FDA to grant remestemcel-L accelerated approval, it may need to address some of the agencys other concerns. Mesoblast said the FDAs response letter identified the need for further scientific rationale to demonstrate the relationship of potency measurements to the products biologic activity.

The comment reflects sections of the briefing document in which the FDA said the quality attributes lack a demonstrated relationship to the clinical performance of specific [drug product] lots. In the absence of evidence of that relationship, the FDA said the attributes may not be sufficient to ensure the manufacturing process consistently produces remestemcel-L lots of acceptable quality.

In disclosing the response letter, Mesoblast said assays measuring the potency of remestemcel-L will continue to be refined to provide further scientific rationale for its use in severe inflammatory diseases with high mortality risk.

Read this article:
Mesoblast hit by FDA rejection, request to run another trial - FierceBiotech

The current report on Stem Cell Therapy Market covers a comprehensive analysis demonstrating actionable insights for clients. In addition, the report offers business insights that encourage them to take suitable decisions which are likely to leverage their business processes. Moreover, the report is a detailed study exhibiting current market trends with an overview of future market study.

Request Sample copy of this report athttps://www.precisionbusinessinsights.com/request-sample?product_id=15608

Some of the players in the Stem Cell Therapy market include:

Cytori Therapeutics Inc. (U.S.), Fibrocell Science (U.S.), Cellartis AB (Cellectis) (France), BioTime, Inc. (U.S.), GE Healthcare (U.S.), Thermo Fisher Scientific (U.S.), STEMCELL Technologies Inc. (Canada), Fujifilm Holdings Corporation (Japan), Vericel Corporation (Aastrom Bioscience) (U.S.), Brainstorm cell therapeutics (U.S.), and Osiris Therapeutics, Inc. (U.S.) to name a few.

PrecisionBusinessInsights has recently launched a latest report on Stem Cell Therapy Market for its clients. This report offers the clients with factual data validated by industry experts and business heads. The report highly involves chapter wise explanation for every aspect of the market wherein the drivers, trends, opportunities, leading and trending segments are discussed in detail with specific examples. Profiles of leading players are also discussed along with their business expansion strategies.

An overview of the Stem Cell Therapy Market report offers a comprehensive analysis for better reference to understand market competition and analysis throughout the forecast period. It also involves key players and their market performance and current developments. It helps you understand the technical jargons that offer ease and convenience to you in understanding the report contents.

RequestCustomization copy of this report athttps://www.precisionbusinessinsights.com/request-customisation?product_id=15608

Geographical markets are covered separately within the report that includes a competitive analysis on their market performance in the base year as well as predictions for the forecast year. Extensive primary research is conducted to carry out leading information in order to understand the market condition and competition within a specified geography. Comparison between two or multiple geographical markets is carried out effectively to know where to invest in.

Key Features of the Report:

What is the Impact of Covid-19 Outbreak on the Stem Cell Therapy?

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our team is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us:

[emailprotected]

PH +1-866-598-1553

See original here:
Stem Cell Therapy Market to Show Incredible Growth by 2025 - The Daily Chronicle

The market research report on the Stem Cell Therapy Market provides a comprehensive analysis of the market dynamics, including development trends, application, types, competitive environment, value chain optimization, and region. Besides this, the report also provides key statistics on the Stem Cell Therapy Market status of the leading market players, key trends, and potential growth opportunities in the market.

The Stem Cell Therapy Market was valued at USD 117.66 Million in 2019 and is projected to reach USD 255.37 Million by 2027, growing at aCAGR of 10.97% from 2020 to 2027.

These study reports are designed with the goal to help the reader in favorable retrieve information and make decisions that are helpful to grow their business. Further, it also provides an examination of the economic synopsis, along with the benefits, drivers, restraints, production, supply, demand, and the level of market growth.

Get a Sample Copy of the Stem Cell Therapy Market Report with Latest Industry Trends @ https://www.verifiedmarketresearch.com/download-sample/?rid=24113

The varying landscape for the overall Stem Cell Therapy industry is offered in the report providing a comprehensive pattern of the Stem Cell Therapy industry and its rapidly changing market landscape. The details mentioned in the report can assist the players in formulating strategies and approaches to gain a robust footing in the industry. Profitable insights and analytical data have been covered in the report to offer insight into global expansion strategies. Each key manufacturer and producer have been thoroughly assessed in the report.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

The market report sheds light on the latest strategic developments and growth patterns of the market players to provide a clear view. The report is an investigative study that provides insights for the players to formulate their business expansion strategies and expand their footing in the market.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113

Table of Content:

Market Overview: This is the first section of the report that includes an overview of the scope of products offered in the Stem Cell Therapy market, segments by product and application, and market size.

Market Competition by Player: Here, the report shows how the competition in the Stem Cell Therapy market is growing or decreasing based on deep analysis of market concentrate rate, competitive situations and trends, expansions, merger and acquisition deals, and other subjects. It also shows how different companies are progressing in the Stem Cell Therapy market in terms of revenue, production, sales, and market share.

Company Profiles and Sales Data: This part of the report is very important as it gives statistical as well as other types of analysis of leading manufacturers in the Stem Cell Therapy market. It assesses each and every player studied in the report on the basis of main business, gross margin, revenue, sales, price, competitors, manufacturing base, product specification, product application, and product category.

Market Status and Outlook by Region: The report studies the status and outlook of different regional markets such as Europe, North America, the MEA, Asia Pacific, and South America. All of the regional markets researched about in the report are examined based on price, gross margin, revenue, production, and sales. Here, the size and CAGR of the regional markets are also provided.

Market by Product: This section carefully analyzes all product segments of the Stem Cell Therapy market.

Market by Application: Here, various application segments of the Stem Cell Therapy market are taken into account for research study.

Market Forecast: It starts with revenue forecast and then continues with sales, sales growth rate, and revenue growth rate forecasts of the Stem Cell Therapy market. The forecasts are also provided taking into consideration product, application, and regional segments of the Stem Cell Therapy market.

Upstream Raw Materials: This section includes industrial chain analysis, manufacturing cost structure analysis, and key raw materials analysis of the Stem Cell Therapy market.

Marketing Strategy Analysis, Distributors: Here, the research study digs deep into behavior and other factors of downstream customers, distributors, development trends of marketing channels, and marketing channels such as indirect marketing and direct marketing.

Research Findings and Conclusion: This section is solely dedicated to the conclusion and findings of the research study on the Stem Cell Therapy market.

Appendix: This is the last section of the report that focuses on data sources, viz. primary and secondary sources, market breakdown and data triangulation, market size estimation, research programs and design, research approach and methodology, and the publishers disclaimer.

Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/need-customization/?rid=24113

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: sales@verifiedmarketresearch.com

Go here to see the original:
Stem Cell Therapy Market Growth Factors, Rising Trends and Outlook 2020 to 2027 - X Herald

In its newly published report, Global Marketers has provided unique insights about the Animal Stem Cell Therapy Market for the given period. One of the major objectives of this report is to categorize the various dynamics of the market and to offer the newest updates such as mergers and acquisitions, various technological developments, new entrants in the market, which make an impact on different segments of the Animal Stem Cell Therapy market. The report also takes into account the impact of the COVID-19 pandemic on the Animal Stem Cell Therapy market and offers a clear evaluation of the future market demand during the forecast period.

Get a Free Sample Report of Global Animal Stem Cell Therapy Market at:

https://www.globalmarketers.biz/report/life-sciences/global-animal-stem-cell-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130268#request_sample

The following manufacturers are covered:

Medivet Biologics LLCVETSTEM BIOPHARMAJ-ARMU.S. Stem Cell, IncVetCell TherapeuticsCelavet Inc.Magellan Stem CellsKintaro Cells PowerAnimal Stem CareAnimal Cell TherapiesCell Therapy SciencesAnimacel

This is likely to drive the Global Animal Stem Cell Therapy Market over the forecast period. This research report covers the market landscape and its advancement prediction in the near future. After studying key vendors, the report focuses on the new entrant contributing to the enlargement of the market. Most companies in the Global Animal Stem Cell Therapy Market have currently adopted new technological trends in the market.

Segmentation by Region Of Animal Stem Cell Therapy Are:

Animal Stem Cell Therapy Market Leading Competition:In this section, the report provides information on Competitive situations and trends as well as merger and achievement and expansion, market shares of the top players. Readers could also be provided with production, revenue, and average price shares by Key vendors.

Ask for Discount at:

https://www.globalmarketers.biz/discount_inquiry/discount/130268

Animal Stem Cell Therapy Market Segment by Type, covers:

DogsHorsesOthers

Animal Stem Cell Therapy Market Segment by Applications, covers:

Veterinary HospitalsResearch Organizations

The Animal Stem Cell Therapy market report is the study of various business viewpoints like challenges geographies, divers, restraints, opportunities, and major players. This Animal Stem Cell Therapy research report was aggregated on the grounds of sub-segments and market sections linked to the sector.

Major Highlights of Animal Stem Cell Therapy Market in the Covid-19 pandemic covered in the report:

Market Competition by key manufacturers in the Animal Stem Cell Therapy industry.

Discussed Sourcing strategies, industrial chain information, and downstream buyers data.

Distributors and traders on Animal Stem Cell Therapy marketing strategy analysis focusing on region-wise needs in the COVID-19 pandemic.

Vendors who are providing a wide range of product lines and intensifying the competitive scenario in the Animal Stem Cell Therapy COVID-19 crisis.

Also highlights the key growth sectors of the Animal Stem Cell Therapy market and how they will perform in the coming years.

Inquire Before Buying at:

https://www.globalmarketers.biz/report/life-sciences/global-animal-stem-cell-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130268#inquiry_before_buying

This Animal Stem Cell Therapy market breakdown also offers the scope of different segments and applications that can in fact impact the market in the future. Thorough information is based on current trends and significant milestones. The Animal Stem Cell Therapy market analysis mentions the volume of sales by region from 2020 to 2024. A thorough evaluation of the limitations included in the market analysis portrays the drivers and gives scope for strategic planning.

Major Highlights:

Detailed overview of parent market

Changing Animal Stem Cell Therapy market dynamics in the industry

exhaustively market segmentation

past, present, and future market size in terms of volume and value

current industry trends and developments

Competitive landscape

Potential and niche segments, geographical regions exhibiting promising growth

Must-have information for market Key vendor to keep going and increase their market footprint

The major key questions addressed through this innovative research report:

Some Points from Table of Content

Global Animal Stem Cell Therapy Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2024

Chapter 1Report Overview

Chapter 2Global Market Growth Trends

Chapter 3Value Chain of Animal Stem Cell Therapy Market

Chapter 4Players Profiles

Chapter 5Global Animal Stem Cell Therapy Market Analysis by Regions

Chapter 6North America Animal Stem Cell Therapy Market Analysis by Countries

Chapter 7Europe Animal Stem Cell Therapy Market Analysis by Countries

Chapter 8Asia-Pacific Animal Stem Cell Therapy Market Analysis by Countries

Chapter 9Middle East and Africa Animal Stem Cell Therapy Market Analysis by Countries

Chapter 10South America Animal Stem Cell Therapy Market Analysis by Countries

Chapter 11Global Animal Stem Cell Therapy Market Segment by Types

Chapter 12Global Animal Stem Cell Therapy Market Segment by Applications

Chapter 13Animal Stem Cell Therapy Market Forecast by Regions (2020-2024)

Chapter 14Appendix

Access full Report Description, TOC, Table of Figure, Chart, etc.at:

https://www.globalmarketers.biz/report/life-sciences/global-animal-stem-cell-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130268#table_of_contents

See the rest here:
Global Animal Stem Cell Therapy Market Professional Survey 2020 by Manufacturers, Regions, Types and Applications, Forecast to 2024 - The Daily...

CRANFORD, N.J., Oct. 7, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, announced that it has signed an exclusive agreement with Novellus Therapeutics Limited ("Novellus") to license iPSC-derived mesenchymal stem cells (iMSCs), and has created a new subsidiary, NoveCite, that will be focused on developing cellular therapies.

NoveCite has a worldwide exclusive license from Novellus, an engineered cellular medicines company, to develop and commercialize NoveCite mesenchymal stem cells ("NC-iMSCs") to treat acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome ("ARDS") associated with COVID-19. Several cell therapy companies using donor-derived MSC therapies in treating ARDS have demonstrated that MSCs reduce inflammation, enhance clearance of pathogens and stimulate tissue repair in the lungs. Almost all these positive results are from early clinical trials or under the emergency authorization program.

NC-iMSCs are the next generation mesenchymal stem cell therapy. They are believed to be differentiated and superior to donor-derived MSCs. Human donor-derived MSCs are sourced from human bone marrow, adipose tissue, placenta, umbilical tissue, etc. and have significant challenges (e.g., variable donor and tissue sources, limited supply, low potency, inefficient and expensive manufacturing). iMSCs overcome these challenges because they:

Globally, there are 3 million cases of ARDS every year out of which approximately 200,000 cases are in the United States. The COVID-19 pandemic has added significantly to the number of ARDS cases. Once the COVID patients advance to ARDS, they are put on mechanical ventilators. Death rate among patients on ventilators can be as high as 50% depending on associated co-morbidities. There are no approved treatments for ARDS, and the current standard of care only attempts to provide symptomatic relief.

"NoveCite iMSCs have the potential to be a breakthrough in the field of cellular therapy for acute respiratory conditions because of the high potency seen in Novellus' pre-clinical studies, and because iMSCs are iPSC-derived, and therefore overcome the manufacturing challenges associated with donor derived cells," said Myron Holubiak, Chief Executive Officer of Citius.

"We are excited to be part of this effort because of the promise to save lives and reduce long term sequelae in patients with devastating respiratory diseases such as ARDS caused by COVID-19," said Dr. Matthew Angel, Chief Science Officer of Novellus. "Our iMSC technology has multimodal immunomodulatory mechanisms of action that make it potentially promising therapy to treat acute respiratory diseases."

About Citius Pharmaceuticals, Inc.

Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit http://www.citiuspharma.com.

About Novellus, Therapeutics, Limited

Novellus is a pre-clinical stage biotechnology company developing engineered cellular medicines using its patented non-immunogenic mRNA high specificity gene editing, mutation-free & footprint-free cell reprogramming and serum insensitive mRNA lipid delivery technologies. Novellus is privately held and is headquartered in Cambridge, MA. For more information, please visit http://www.novellus-inc.com.

About NoveCite iMSC (NC-iMSC)

NoveCite's mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process. The NC-iMSCs produced from this clonal technique are differentiated from human donor-derived MSCs (bone marrow, placenta, umbilical cord, adipose tissue, or dental pulp) by providing genetic homogeneity. In in-vitro studies, NC-iMSCs exhibit superior potency and high cell viability. NC-iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19. NC-iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from a master cell bank.

First generation (human donor-derived) MSCs are isolated from donated tissue followed by "culture expansion". Since only a relatively small number of cells are isolated from each donation, first generation MSCs are increased by growing the cells in culture. Unfortunately, these type of MSCs start to lose potency, and ultimately become senescent. Each donation produces a limited number of MSCs, so a continuous supply of new donors is needed to produce commercial scale. The number and quality of MSCs that can be isolated from different donors can vary substantially.

About Acute Respiratory Distress Syndrome (ARDS)

ARDS is an inflammatory process leading to build-up of fluid in the lungs and respiratory failure. It can occur due to infection, trauma and inhalation of noxious substances. ARDS accounts for approximately 10% of all ICU admissions and almost 25% of patients requiring mechanical ventilation. Survivors of ARDS are often left with severe long-term illness and disability. ARDS is a frequent complication of patients with COVID-19. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risks associated with developing the NoveCite technology as a treatment for ARDS; risks associated with developing any of our product candidates, including any licensed from Novellus, Inc., including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; our need for substantial additional funds; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development, including the NoveCite technology; our ability to obtain, perform under and maintain licensing, financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:Andrew ScottVice President, Corporate Development(O) 908-967-6677 x105(M) 646-522-8410ascott@citiuspharma.com

View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-signs-an-exclusive-worldwide-licensing-agreement-with-novellus-therapeutics-for-unique-imsc-therapy-for-acute-inflammatory-respiratory-conditions-including-covid-19-related-acute-respiratory-distress-syndrom-301147409.html

SOURCE Citius Pharmaceuticals, Inc.

Company Codes: NASDAQ-SMALL:CTXR

More:
Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory...

Abu Dhabi: UAE's Abu Dhabi Stem Cells Centre (ADSCC) is collaborating with Israeli regenerative medicine company, Pluristem, to advance COVID-19 therapies.

In a statement, ADSCC said it was working to administer Pluristem developed PLX cells via a nebuliser to COVID-19 patients. The collaboration will allow ADSCC to expand its stem cell therapy options with the novel PLX cells, while also enabling Pluristem to leverage the ADSCCs nebuliser administration experience to develop a new treatment delivery model for PLX cells.

ADSCC has reported effective usage of nebulisers to treat patients suffering from COVID-19 infection, with stem cells sourced from the patients own blood.

Further discussions are also ongoing to treat chronic Graft Versus Host Disease (cGvHD) a life-threatening immune response to the donors stem cells against the host (patient).

Both projects follow a recently-signed agreement between ADSCC and Pluristem to harness the power of regenerative medicine.

Continued here:
Abu Dhabi Stem Cells Centre collaborating with Israeli firm for COVID-19 therapies - Gulf News

BOSTON, Oct. 1, 2020 /PRNewswire-PRWeb/ --Adapting to the present COVID crisis, this year the 2020 Outsourcing in Clinical Trials USA Conference, one of several international clinical trials supply trade conferences organized by Arena International Events Group each year, adopted a virtual meeting format. The conference, scheduled for September 30-October 1, continued its tradition of bringing together contract research organization suppliers and company sponsors in the clinical trials supply industry to discuss new developments and best practices.

Among the many industry members invited to speak in the event, James L. Sherley, M.D., Ph.D., founder and director of Massachusetts stem cell biotechnology company Asymmetrex, presented on September 30. Dr. Sherley's presentation highlighted a growing new area of the clinical trials supply industry. More and more, the clinical trials supply industry is considering better technology and practices to support stem cell clinical trials and gene therapy clinical trials that utilize advanced therapy medicinal products. In particular, Dr. Sherley discussed the value of implementing new quantification technologies for ATMPs developed with tissue stem cells. He answered the rhetorical question that was the title of his talk "How can we outsource stem cell clinical trials without counting tissue stem cells?" by detailing places in ATMP supply chains where instituting counting technologies would provide significant benefits to the stem-gene clinical trials supply industry and the patients it serves.

Sherley also presented innovation proposals for traditional pharmaceutical and biopharmaceutical clinical trials supply. He described how tissue stem cell counting technologies represented advantages both for discovery of novel drugs and for toxicology evaluations of new drug candidates. A major value presented was the opportunity for drug companies to realize hundreds of millions of dollars in reduced costs each year by using tissue stem cell counting tests for earlier identification of drugs that would fail late in clinical trials because of inducing chronic failure of organs and tissues like the liver and bone marrow. Currently applied animal toxicology studies miss many drugs with this disastrous character. Sherley described how such drugs could be detected in inexpensive cell culture tests by counting how stem cell-specific number and viability changed in their presence.

Though not a main focus of the presentation, Sherley ended his presentation with acknowledgement of Asymmetrex's recent introduction of the first-in-kind technology for counting therapeutic tissue stem cells and determining their dosage. The company holds issued patents for the technology and its use for drug evaluations in both the U.S. and U.K. In August of this year, it published a peer-reviewed report, co-authored with its partner AlphaSTAR Corporation, that describes the new method and its applications for stem cell therapy and drug evaluations. In September, the company was awarded a research and development grant from the National Institutes of Health-National Heart, Lung, and Blood Institute for continued development of the technology and its commercialization. These plans for the company's AlphaSTEM Test tissue stem cell counting technology were recently reported.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The company's U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the "AlphaSTEM Test") for use in stem cell transplantation therapies and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

SOURCE Asymmetrex LLC

Read the rest here:
Asymmetrex Presents the Value of Tissue Stem Cell Counting For Supplying Stem Cell Clinical Trials and Drug Development Clinical Trials - Benzinga

The global platelet rich plasma & stem cell alopecia treatment market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on treatment, indication, end-user, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises a competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides presence of key players working in the development of stem cell and platelet rich pharmaceutical products, thereby presenting a thorough analysis of the overall competitive scenario in the global platelet rich plasma & stem cell alopecia treatment market.

This report analyzes the current and future scenario of the global platelet rich plasma & stem cell alopecia treatment market for the period 2018 to 2026. Rise in awareness about platelet rich plasma therapies and stem cell therapies, increase in funding for alopecia treatment research and stem cell research, and increase in the incidence of autoimmune hair loss disorders are likely to be major drivers of the global platelet rich plasma & stem cell alopecia treatment market during the forecast period.

Request Brochure for Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=55800

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment market Witness Most Promising Rise in Demand

The global platelet rich plasma & stem cell alopecia treatment market is expected to reach a value of approximately US$ 450.5 Mn by the end of 2026, expanding at a high single digit CAGR during the forecast period. Factors such as increase in demand for accurate and prompt treatment of alopecia and advancements in platelet rich plasma and stem cell therapies that have revolutionized the diagnostic science are likely to boost the market. Moreover, a rise in awareness about platelet rich plasma therapies and stem cell therapies is expected to drive the global market during the forecast period.

Increased awareness has driven demand for platelet rich plasma therapy & stem cell therapy in the past few years in countries such as Japan, India, Brazil, and Russia and developed regions such as North America and Europe. Additionally, private players are actively promoting the advantages of treatment of alopecia with stem cell therapy across the globe. A rise in the incidence rates of autoimmune hair loss disorders such as alopecia is estimated to boost the platelet rich plasma & stem cell alopecia treatment market. According to the Journal of Clinical, Cosmetic, and Investigational Dermatology, 2015, the lifetime incidence rate of alopecia areata is approximately 2% worldwide. This is expected to propel the market. However, a lack of treatment approval and high cost of alopecia treatment are likely to hinder the growth of platelet rich plasma & stem cell alopecia treatment market.

Request for Analysis of COVID19 Impact on Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=55800

Based on treatment, the global platelet rich plasma & stem cell alopecia treatment market has been segmented into platelet rich plasma therapy and stem cell therapy. The stem cell therapy segment has been further classified into bone marrow treatment and adipose treatment. In terms of indication, the global platelet rich plasma & stem cell alopecia treatment market has been classified into androgenic alopecia, congenital alopecia, cicatricial or scarring alopecia and others. Based on end-user, the global platelet rich plasma & stem cell alopecia treatment market has been divided into hospitals, dermatology clinics, and others. The market size and forecast for each of these segments have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year.

Key Players of Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report:

Major players operating in the global platelet rich plasma & stem cell alopecia treatment market include Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, Inc., RepliCel Life Sciences, Histogen, Inc., and Glofinn Oy. Key players are focused on research & development of alopecia treatment by investing in platelet rich plasma & stem cell alopecia therapies. Mergers & acquisitions, collaborations, and partnerships are helping companies expand their footprint and further develop effective treatments for alopecia.

Buy Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=55800&ltype=S

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

See original here:
Platelet Rich Plasma and Stem Cell Alopecia Treatment Market -Key Players, Size, Growth, Incredible Potential, and Stagnant Progress According to New...

TORONTO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (CB2 or the Company), one of the largest integrative healthcare systems in the United States, is pleased to announce that it has completed the asset acquisition of Maverick County Medical (MCM) in Eagle Pass, Texas. The acquisition of MCM expands the Companys bricks and mortar and telemedicine services to 14 States and adds 10,300 new patients to its current roster of 100,000.

MCM has been operating in Eagle Pass for over 15 years with strong patient retention. Services to patients include primary care, occupational medicine, disease management, minor surgeries, and treatment for auto accident injuries, among others. Services provided by MCM are primarily reimbursed through insurance carriers including Medicare, Medicaid and other commercial payors. MCM also provides services for un-insured patients however representing a smaller proportion of todays revenues.

The Company expects to see continued growth in patient registrations and visits as MCM continues to thrive among the challenges most clinics have faced due to the recent COVID-19 pandemic. Further, the Company will work quickly to expand on the current offering of services by leveraging its current telemedicine infrastructure to provide access to patients across the state of Texas. The Company will also evaluate the current services offered to determine growth in new and complimentary services, add new lines of revenue from insurable services, and expand overall patient care.

Our goal is to provide accessible and affordable healthcare solutions, said Prad Sekar, CEO, CB2 Insights. With the expansion into Texas by way of acquisition of MCM, we welcome a family of practitioners, staff and doctors who align with the direction of our Company, and will be a central point of expansion for our services through telemedicine, subscription services for uninsured patients, and the vision for an integrated National healthcare network.

MCM represents the first acquisition by the Company since its recently announced oversubscribed private placement of CAD 5.13 million in September 2020. The acquisition is also part of a 3-pronged growth model which includes growth from the current infrastructure, new services and acquisitions. The Companys experienced management team continues to develop a robust pipeline of accretive and strategic acquisition targets that are revenue generating, profitable and offer significant opportunities for growth.

The Company paid a total cash consideration of CAD 0.98 million for MCM. Terms of the transaction include a customary transition by the previous owners with 50% of the cash awarded at the signing of the transaction, and 50% due 6 months from the date of completion of the transaction. MCM reported revenues in 2019 of CAD 1.6 million and net income of CAD 0.29 million.

About CB2 Insights

CB2 Insights (CSE:CBII OTCQB:CBIIF) is a healthcare services and technology company, working to positively impact patient health outcomes. The Companies mission to improve the lives of patients through the prevention and treatment of health conditions and using proprietary technology to monitor, assess, and generate insights to help improve patient outcomes. The Company owns and operates a proprietary virtual telehealth platform, and a network of over 30 medical clinics across 13 states in the US, providing integrative, primary and urgent care services to over 100,000 patients annually.

The Company has created works primarily to roster and treat patients seeking traditional and alternative treatments due to the ineffectiveness of conventional medicine, inability to find support through their existing care network, or in some cases, inability to access a primary care network. The Company offers both primary care via a traditional insurable services model and a disruptive low-cost subscription based urgent care offering for patients seeking immediate need to a healthcare provider via telehealth.

The Company differentiates itself by being one of the largest integrative medical practices in the US that owns its own proprietary technology, data analytical assets, and clinical research expertise to support new market expansion, market access, data collection and analysis and drug discovery.

The Company operates a proprietary electronic health record platform Sail (Sail) to document, treat, monitor and report on patient health outcomes. Developed in 2015, Sail is used internally across all of the Companys clinical operations. Sail features a robust telemedicine platform that the Company uses to provide care to its National patient base. To support patient care and positive health outcomes, the Company is also focused on advancing safety and efficacy research surrounding alternative health treatments by monitoring and assessing Real-World Data (RWD) and providing Real-World Evidence (RWE) through our proprietary technology, data analytics, and a full service contract research organization.

For more information please visit http://www.cb2insights.com or contact:

Investor RelationsJonathan L. Robinson CFAOak Hill Financialjrobinson@oakhillfinancial.ca416-669-1001

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2s filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding the Companys unaudited financial results and projected growth.

Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein.

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.

Read the original post:
CB2 Insights Announces Acquisition of Texas-based Primary Care Medical & Wellness Clinic with $1.6 million in Revenue and Positive EBITDA -...

For as long as humans have existed, they have told stories to each other. But what about the stories people tell themselves? A breakthrough documentary, Is Your Story Making You Sick? offers a compelling look at how stories define how people see themselves, view relationships, live their lives and manage their health.

Dr. Uday Jani, a respected Milton internist who specializes in integrative medicine, and Lewes chiropractor Dr. Krista Griffin invite the community to watch this award-winning film. An outdoor screening will be held at 7 p.m., Thursday, Oct. 15, at Leftys Alley & Eats, 36450 Plaza Blvd., Lewes. Other screenings set to be held Oct. 8 and 10 in Leftys banquet room are being reworkeddue to changing COVID conditions in the community. A Zoom webinar is being planned; check Dr. Janis website at udayjanimd.com for details on how to participate.

The film features eight people from all walks of life who bravely confront their stories, along with top national mental health experts and a revealing look at narrative therapy exercises and modalities.

This is an important film showing an innovative approach to healing through the real-life journeys of people living with addiction, trauma, depression and anxiety who learn how to confront and ultimately change their stories, said Jani. In this time of COVID anxiety, loneliness and isolation, the baggage people carry may seem heavier than before. But as this documentary shows, there are many tremendously effective modalities that can start the healing.

Jani, who utilizes mind-body practices to care for his patients, credits his fellowship studies at the Arizona Center for Integrative Medicine, and particularly his mentor there, Dr. Ann Marie Chiasson, who appears in the documentary.

It is possible to overcome addiction, PTSD, depression and other stress-related illnesses by re-examining the stories we tell ourselves, said Jani. Finding whats at the root of each individual patients story is how you begin to rewrite the story and begin the process of transcending pain.

The documentary expertly weaves years of filming and research, intensive narrative group therapy, and expertise from leaders in the fields of trauma, addiction, and mindfulness to illustrate the road to meaningful change.

The story problem can manifest in many different ways, and frequently results in a variety of incorrect diagnoses and unneeded drug treatments, said Jani. Learning how to monitor and modify patterns that trigger symptoms allows new patterns to be created and a new story to evolve. The power of healing mind, body and spirit with community involvement has become even more essential during this time of COVID.

Griffin said, Everyone should see this movie. It demonstrates the power childhood emotional traumas have over choices throughout ones life. The message of resilience and overcoming is beautifully encouraging and hopeful.

We so appreciate the swift and enthusiastic participation of Leftys owner DJ Hill, who has graciously made his facility available to the community for viewing this important film, said Jani. He has ensured every protocol, from mask wearing to social distancing, is scrupulously followed to keep us all safe.

The film screenings include a live Q&A immediately following the documentary, with Jani and Griffin joined by integrative health specialist Dr. Carolyn Trasko and clinical psychologist Dr. Richard Todd. Proceeds from ticket sales will benefit the Harry K Foundation, dedicated to defeating childhood hunger in Delaware.

For a preview, watch the trailer at youtu.be/zOpUK50JN1g.

Visit link:
Jani and Griffin to host outdoor documentary screening Oct. 15 at Lefty's - CapeGazette.com

What Is a Holistic Veterinarian, and How to Find the Right One for Your Pet?

These experts are trained in natural remedies such as food, herbal medicine, and acupuncture.

Natural remedies such as food, herbal medicine, and acupuncture aren't just for humans. They are treatments for your dog, cat, or guinea pig, too, and they come from a holistic veterinarian, who uses a combination or conventional medicine and natural remedies to treat your pets' ailments.

But holistic veterinarians do more than use natural remedies. "A holistic veterinarian is looking at the pet as a whole, where everything is connected, versus just treating symptoms," explains holistic veterinarian Dr. Katie Woodley, DVM. They're concerned with sousing out the root cause of a problem, she says, and then treating that underlying issuenot just reducing its symptoms. For example, if your pet has an allergy, a conventional veterinarian might treat the problem with steroids, but the problem could return as soon as steroids are no longer administered, Dr. Woodley says. But a holistic veterinarian would look for the root cause of the allergic reactionsuch food or environmentand seek to resolve the issue in a way that does not come back, she says.

Anna Avdeeva / Getty Images

There's nothing wrong with conventional medicine, of course. Both conventional and holistic "methods have their strengths and weaknesses," says Dr. Gary Richter, DVM, owner of Montclair Veterinary Care and Rover health expert, who practices integrative medicine, which is a combination of both methods.

Related: Try One of These Alternative Treatments for Your Pet's Holistic Health

Both conventional and holistic veterinarians receive the same conventional medicine training, but holistic veterinarians further their education through the study of practices such as food therapy, herbal medicine, acupuncture, homeopathy, aromatherapy, and more, Dr. Woodley explains. Pet parents might seek a holistic veterinarian for a number of reasons, Dr. Richter says: They might prefer a holistic philosophy for their own healthcare, and want their pet to experience the same. Or, he says, they've tried conventional medicine and haven't seen the results they ideally want. A pet that's in pain, for example, may not improve with medicationbut a holistic veterinarian could try acupuncture, supplements, or herbal medicine to aid other medications, Dr. Woodley says.

Other unique treatments and services holistic veterinarians may offer could include chiropractic care, ozone therapy, or homotoxicology, says Dr. Richter, who adds that "some [treatments] are more scientifically based than others and what specific therapies are offered by a holistic veterinarian varies greatly based on their education, experience, and personal philosophy."

To find the best holistic veterinarian for youand for your pet's needsDr. Richter recommends going to the American Holistic Veterinary Medical Association's website, where you can search for holistic veterinarians in their area. There, you'll also be able to see what unique certifications a veterinarian hasso, for example, if you think your pet needs acupuncture, you can filter the results to find holistic veterinarians that provide acupuncture service in your area, Dr. Woodley says. It's always smart to check reviews too, she adds, "to see if other people have found them helpful for the care of their pet." Perusing their website and social media might help you get a sense of their philosophy, she says, and help you to determine "if it resonates with you as a pet parent."

The rest is here:
What Is a Holistic Veterinarian, and How to Find the Right One for Your Pet? - Yahoo Lifestyle

While it may seem like ginger is a recent trend in holistic and alternative treatments, the plant, which originated in Southeast Asia, has been used for medicinal purposes in countries like India and China for centuries. In fact, many Asian households used it to help treat anything from a headache to a sore throat to menstrual cramps long before studies and scientific evidence proved gingers health benefits.

Healthy Brain Foods You Should Be Eating

According to a study discussing the effectiveness of ginger in the journal Integrative Medicine Insights, the anti-nausea properties of ginger come from gingerols, which are natural anti-inflammatory and antioxidant compounds found in raw ginger that activate spice receptors on the tongue.

If you've ever had ginger ale or ginger tea to settle an upset stomach, you already know that ginger can help with nausea and digestive problems. But to get the largest amount of health benefits from ginger, you should be consuming it raw.

Along with its anti-nausea properties, ginger also stimulates gastric emptying, moving things out of the stomach more quickly and thus providing relief to tummy troubles.

Beyond its use for nausea, ginger is also packed with nutrients that benefit both the body and brain andwhile these healing properties are present in many of its forms, you might consider having a few fresh ginger roots on hand.

In 2013, researchers studied the antiviral effects of both fresh and dried ginger on a respiratory virus in human cells. The study indicated that fresh ginger was an effective tool in protecting the respiratory system, while the dried ginger was not.

Raw ginger is a low-cost and easy-to-find natural remedy that you can use to help treat several everyday issues like sore throats and headaches. If youre unsure how to consume raw ginger, there are a few different ways.

The first is to mince raw ginger and blend it up in a healthy fruit smoothie. To lessen the zing, use fruits that have a lot of sweet flavor like fresh mangos. In this recipe for a mango smoothie with turmeric green tea and ginger, matcha powder adds a soft earthiness that tones down the sharp ginger.

Another option is to add a chunk of ginger to a hot cup of tea or hot water. You dont even have to peel it simply place a piece of ginger in your teacup and pour boiling water over it. Add some honey and a squirt of fresh lemon if you like, and youve got the perfect remedy for fall sniffles.

You can also grate some ginger into your favorite comforting or spicy soup. When you grate ginger as opposed to dropping it in raw, the result is milder and much more dispersed. Its a staple in Indian cooking and brings both heat and a slightly spicy, slightly sweet flavor.

If youre more of an amateur baker, you can also add chopped pieces of ginger to muffins or cake batter or try pumpkin desserts with fresh ginger for a zesty fall twist.

But if you dont want to whip up a recipe, you can eat it raw just as is you only need a tiny sliver to chew on. Cut an inch off the ginger root, use a spoon to peel the brown skin off and nibble on it. You can also use a vegetable peeler to shred super thin slices of ginger and let them sit on your tongue before chewing them down for a less pungent experience.

If youre not familiar with storing raw ginger, it can last in the fridge for three to four weeks and even longer in the freezer. Simply place the root in the vegetable drawer or in an eco-friendly produce bag to keep it fresh, and when youre ready to use it, you can use a grater or zester to grate the frozen piece of ginger right in without needing to thaw it.

Visit link:
What Are the Good Benefits of Ginger? - The Daily Meal

Newswise Irvine, Calif. September 30, 2020 In a new study, published in Current Biology, researchers from the University of California, Irvine School of Medicine reveal how subanesthetic ketamine, which is used for pain management and as an antidepressant in humans, is effective in treating adult amblyopia, a brain disorder commonly known as lazy eye.

Our study, demonstrates how a single-dose of subanesthetic ketamine reactivates adult visual cortical plasticity and promotes functional recovery of visual acuity defects resulting from amblyopia, explained Xiangmin Xu, PhD, a professor of anatomy and neurobiology and director of the Center for Neural Circuit Mapping at the UCI School of Medicine.

Subanesthetic ketamine, commonly used to treat depression and pain, evokes rapid and long-lasting antidepressant effects in human patients. There was evidence that ketamine may control how the nervous system makes structural changes in response to internal and external demands, a process called neural plasticity. But, how the drug worked remained elusive, until now.

Our research team showed that ketamine down-regulates NRG1 expression in PV inhibitory cells, resulting in sustained cortical disinhibition to enhance cortical plasticity in adult visual cortex, said Steven F. Grieco, PhD, a postdoctoral scholar in the Xu lab and lead author. Through this neural plasticity-based mechanism, ketamine mediated functional recovery from adult amblyopia. Xin Qiao, PhD, a postdoctoral staff in the Xu lab is a co-first author for the published paper.

Amblyopia is a vision disorder in which the brain fails to process inputs from one eye, favoring the other eye. The condition can result in decreased vision in the affected eye. Each year, between one and five percent of children worldwide, are diagnosed with this condition.

Fast and sustained ketamine actions show promise for therapeutic applications that rely on reactivating adult cortical plasticity. Further testing is needed to determine the full implications of this discovery.

This study was supported in part by grants from the National Institutes of Health.

About the UCI School of Medicine

Each year, the UCI School of Medicine educates more than 400 medical students, and nearly 150 doctoral and masters students. More than 700 residents and fellows are trained at UCI Medical Center and affiliated institutions. The School of Medicine offers an MD; a dual MD/PhD medical scientist training program; and PhDs and masters degrees in anatomy and neurobiology, biomedical sciences, genetic counseling, epidemiology, environmental health sciences, pathology, pharmacology, physiology and biophysics, and translational sciences. Medical students also may pursue an MD/MBA, an MD/masters in public health, or an MD/masters degree through one of three mission-based programs: the Health Education to Advance Leaders in Integrative Medicine (HEAL-IM), the Leadership Education to Advance Diversity-African, Black and Caribbean (LEAD-ABC), and the Program in Medical Education for the Latino Community (PRIME-LC). The UCI School of Medicine is accredited by the Liaison Committee on Medical Accreditation and ranks among the top 50 nationwide for research. For more information, visit som.uci.edu.

Read the original:
New study finds antidepressant drug effective in treating lazy eye in adults - Newswise

"The mind and the body are so intertwined," Fulop says. "If a person is dealing with the constant stresses of daily life it is likely to manifest in physical aches and pains in the body." To break it down: When the brain releases stress hormones, triggering the fight-or-flight response, heart rate and blood pressure can increase. When these two vitals go up, Fulop says the muscles will tighten.

"When muscles will stay in a contracted state and shorten, pain will eventually set in," she says. "How we treat our body through our eating habits, exercise habits, and dealing with stress will play an extremely important role in our overall health and wellness."

On top ofthat, living with chronic pain will begin to change how the body processes pain over time, Nerurkar says. "And long-standing chronic pain can have an impact on the mind-body connection." Managing these symptoms before they become chronic can increase the overall quality of life.

More:
Clenched Teeth? How That Tension Might Affect The Rest Of The Body - mindbodygreen.com

A Vanderbilt team of experts in virology, genetics, structural biology, chemistry, physiology, medicine, immunology and pharmacology have together developed technology to understand and predict animal susceptibility to SARS-CoV-2, the scientific name for the strain of coronavirus causing COVID-19. providing evidence that horses and camels may be at increased risk of the virus. The group has also released a publicly available tool to enable people to understand the likelihood of other animals susceptibility.

The article, Predicting susceptibility to SARS-CoV-2 infection based on structural differences in ACE2 across species, was published in the Federation of American Societies for Experimental Biology (FASEB) Journal on Oct. 5.

The investigators applied a combination of sophisticated genetic sequence alignment and structural analysis of ACE2, the receptor protein for SARS-CoV-2, to a variety of known susceptible and non-susceptible species. Through the analysis they identified five particular amino acid sites within the protein that distinguish virus susceptibility or resistance, and using these sites developed an algorithm to predict susceptibility of unknown species. The algorithm has been made public on a website where people can upload the aligned ACE2 sequence of animals with unknown susceptibility to generate a COVID-19 susceptibility score.

Jacquelyn Brown, a staff scientist at the Vanderbilt Institute for Integrative Biosystems Research and Education, initiated the project. When I first learned that COVID-19 had crossed the species barrier into cats and dogs, I became worried about other animals that might act as reservoirs for the disease or be at risk, explained Brown, an avid equestrian who practices medieval mounted archery. Since MERS infects camels, I was concerned about what would happen if my horse could get it?! Horses have massive lungs and a sensitive respiratory system, and we humans often touch their noses and mouths.

206,000 horses live on horse farms and properties in Tennessee and 3.2 million of the states 10 million farm acres are devoted to the horse industry. Brown proposed a collaborative research project on the topic to Gordon A. Cain University Professor John Wikswo, who holds appointments in physics, biomedical engineering, and molecular physiology and biophysics.

As the director of VIIBRE, an institute established to foster and enhance interdisciplinary research in the biophysical sciences, bioengineering and medicine at Vanderbilt, Wikswo immediately assembled a trans-institutional team spanning Vanderbilt schools and colleges and Vanderbilt University Medical Center. I speak each disciplines language well enough to make the necessary connections, Wikswo said. This proved to be an outstanding group brought together by their interests and skills that produced an important result in very short order.

The project gave meaning to each researcher, at a time when we all were searching for ways to contribute to fighting COVID-19, noted Wenbiao Chen.

The work could not have been achieved without the collaboration of many researchers. The multidisciplinary approach revealed how much information can be wrung from the same basic information, noted Wenbiao Chen, the papers co-corresponding author and associate professor of molecular physiology and biophysics. We found potential targets by sequence comparison but wouldnt have been able to interpret our findings without structural information. The project gave meaning to each researcher, at a time when we all were searching for ways to contribute to fighting COVID-19.

Understanding the animals we should more closely scrutinize based on their susceptibility to COVID-19 can help us protect people, pets, wildlife, livestock and our food sources, said Matthew Alexander, assistant professor of medicine. The algorithm the team developed is particular to SARS-CoV-2 because it focuses on its particular receptor binding protein ACE2, but the approach is broadly applicable to predicting susceptibility to other viruses or during future outbreaks.

There is also the opportunity to investigate if the identified five sites on ACE2 that most distinguish susceptible from non-susceptible species can be used as targets to develop drugs that inhibit these sites specifically. I hope that our results will inspire future research on both rational drug design and closer examination of at-risk species, said Meena Madhur, the papers co-corresponding author, associate professor of medicine and associate director of the Vanderbilt Institute for Infection, Immunology and Inflammation at VUMC.

Of note, the work and collaboration were conducted remotely, with an analysis of publicly available data. This experimental approach of using extensive and rapidly accumulating publicly available data in new ways allowed us to efficiently answer a timely question without having to generate new datasets. The collaboration was fun and rewarding, and we were able to answer an important question that none of us could have solved alone, Alexander, the papers co-first author said. Wikswo pointed out that while the source data was public, the project required massive calculations of how different versions of the virus would bind to each animals ACE2.

Members of the collaborative project also include Distinguished Research Professor of Chemistry Jens Meiler, Clara Schoeder, co-first author and postdoctoral scholar, , Charles Duncan Smart, graduate student in molecular physiology and biophysics, Chris Moth, computational chemist in the biological sciences department, and Tony Capra, research associate professor of biological sciences.

The work was supported by National Institutes of Health grants F32HL144048-01, DK117147, UH3TR002097 and U01TR002383, U19AI117905, U01AI150739, and R01AI141661, R35GM127087, and DP2HL137166 and American Heart Association grants 20PRE35080177 and EIA34480023

More:
Vanderbilt researchers develop publicly available COVID-19 animal susceptibility prediction tool; suggests increased risk to horses - Vanderbilt...

Most mornings can benefit from a cup of coffee, but that doesn't mean every morning should start with a cup of coffee.

"Something that's become a big game-changer for me is starting the morning off with two large glasses of water," Bulsiewicz says. "I have not given up coffee. I will not give up coffee. I've just found that my body responds better when I reach for water first."

Think about it. To avoid waking up in the middle of the night to pee, urologist Vannita Simma-Chiang, M.D., recommends taking a final sip of water about three hours before bed. If people follow that rule, by the time they wake up, about 11 hours will have passed without any source of hydration.

"Your body needs that water to start working properly," Bulsiewicz says. "My brain, my gut, and my kidneys all seem to function better when I start with water instead of coffee."

Visit link:
Cold Water Therapy & Hot Coffee: A GI Doc Shares His Morning Routine Essentials - mindbodygreen.com

Joseph Duffy PhD brings 20+ years of small molecule discovery chemistry and operations to his role as SVP Chemistry of Skyhawk Therapeutics, Elliot Ehrich MD brings 20+ years of clinical development for novel pharmaceuticals to his role as Chief Medical Officer of Skyhawk Therapeutics,and Rob Hershberg MD-PhD with 25+ years of biotech and pharma experience has joined Skyhawk's Scientific Advisory Board.

WALTHAM, Mass., Oct. 5, 2020 /PRNewswire/ -- Skyhawk Therapeutics today announced that Dr. Elliot Ehrich has joined the Company as Chief Medical Officer and Dr. Joseph Duffy has joined as Senior Vice President of Chemistry. The Company also strengthened its Scientific Advisory Board with the addition of Dr. Rob Hershberg.

"We are delighted that Joe and Elliot have come on board at Skyhawk," said Bill Haney, co-founder and CEO of Skyhawk Therapeutics. "Their combined scientific and clinical accomplishments will be invaluable in shepherding our novel RNA-targeting small molecule drug candidates successfully into the clinic. We are also excited to welcome Rob to our Scientific Advisory Board. His clinical and scientific insight and deep experience as a drug developer will be a tremendous addition to Skyhawk."

Elliot Ehrich, MD most recently served as a Venture Partner at 5AM Ventures and Chief Medical Officer (CMO) at Expansion Therapeutics, a 5AM Ventures portfolio company. Previously, Dr. Ehrich spent 17 years at Alkermes ultimately as Executive Vice President of R&D and CMO. At Alkermes he led the development and successful FDA registration of multiple new medicines. Dr. Ehrich has also worked in clinical pharmacology and clinical research at Merck &Co, Inc..

Dr. Ehrich received a BA in biochemistry from Princeton University and an MD from Columbia University. He completed a residency in internal medicine and a fellowship in immunology and rheumatology at Stanford University Medical School followed by postdoctoral research the Department of Microbiology and Immunology.

Over the past four years, Joseph Duffy PhD, served as Executive Director of Discovery Chemistry atMerckResearch Laboratories in Rahway and Kenilworth, New Jersey, where he oversaw multiple preclinical drug discovery teams. Dr. Duffy's contributions over 24 years at Merck included all phases of drug discovery, from lead identification through clinical phase candidate development. He directed successful lead optimization efforts for multiple indications, resulting in clinical candidates and Investigational New Drug (IND) applications from both internal projects and international collaborative research with biotech organizations. Dr. Duffy received his B.Sc. in Chemistry from Kent State University and his Ph.D. from Harvard University.

Rob Hershberg MD-PhD began his career as an Assistant Professor at Harvard Medical School and an Associate Physician at Brigham and Women's Hospital in Boston. Later, Dr. Hershberg co-founded VentiRx Pharmaceuticals and, as President and Chief Executive Officer, led the company through its transformational partnership with Celgene. Dr. Hershberg joined Celgene in 2014 to lead their efforts in Immuno-Oncology, was promoted to Chief Scientific Officer in 2016, and was subsequently Executive Vice President and Head of Business Development & Global Alliances and served as a member of the Executive Committee until the acquisition of Celgene by Bristol-Myers Squibb in 2019. Rob is currently a Venture Partner on the Frazier Life Sciences team. He completed his undergraduate and medical degrees at the University of California, Los Angeles and received his Ph.D. at the Salk Institute for Biological Studies.

Dr Hershberg joins Skyhawk's distinguished Scientific Advisory Board which includes:

Skyhawk Therapeutics is committed to discovering, developing and commercializing therapies that use its novel SkySTARTM (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) platform to build small molecule drugs that bring breakthrough treatments to patients.

For more information visit: http://www.skyhawktx.com, https://twitter.com/Skyhawk_Tx, https://www.linkedin.com/company/skyhawk-therapeutics/

SKYHAWK MEDIA CONTACT:Anne Deconinckanne@skyhawktx.com

View original content:http://www.prnewswire.com/news-releases/skyhawk-therapeutics-expands-leadership-team-with-chief-medical-officer-and-head-of-chemistry-and-adds-to-its-scientific-advisory-board-301145628.html

SOURCE Skyhawk Therapeutics

Here is the original post:
Skyhawk Therapeutics Expands Leadership Team with Chief Medical Officer and Head of Chemistry, and adds to its Scientific Advisory Board - BioSpace

New Zealand, which will go into elections on October 17, will also be holding a referendum to decide whether cannabis should be legalised or not.

If New Zealanders are to vote for legalising cannabis for recreational usage, it would join the likes of countries such as Canada, Uruguay and certain states in the United States where consumption of marijuana is legal. Early poll numbers, from the latest Newshub Reid-Research poll, however, reveal that only 37.9 per cent population support the proposition.

In India, the investigations into Sushant Singh Rajputs death has thrown open a Pandoras box of drug abuse in Bollywood. The arrest of actor Rhea Chakraborty by the Narcotics Control Bureau (NCB) over the discovery of 59 gms of curated marijuana seized, and the questioning of lead Bollywood actors such as Deepika Padukone over certain WhatsApp chats which referred to maal and hash, has brought back a much-debated topic - that of legalisation of marijuana.

Also known as Weed, Pot or Ganja, Marijuana is the most commonly used illegal drug in the world.

Around 3 crore people use it in India, alone, with Delhi the third-largest cannabis consumer in the world and Mumbai, the 6th largest.

India also grows some of the most sought after varieties of weed in the world the stunning Parvati Valley in Himachal Pradesh is a Hippies paradise, where the hugely popular Malana weed is cultivated. Keralas Idukki Gold is renowned as one of the best strains of weed in Asia.

Ariel view of and from the mountain village of Malana, India. The place lushes with greenery in the summers, but as it is at 10000 ft, conical rooftops are made to stand the snowfalls of the winter. Its famous for its Quality Hashish, 5K

India is no stranger to marijuana, a drug that has been used for thousands of years, dating back as far as 4000 BC. The cannabis plant even finds a mention in the Vedas and is closely associated with Lord Shiva. The drink Bhang or thandai served during Holi is prepared from dried cannabis leaves and milk, with other spices added to it. Bhang is legal in the country and is sold at specific government authorised shops.

Weed also has a connection with Ayurveda, which, while connoted as a toxic substance in Ayurvedic texts, has traditionally been used in medicines. In 2018, the Centre Council for Research in Ayurvedic Sciences in collaboration with Gujarat Ayurved University found that cannabis leaves can be effective in alleviating pain and other symptoms in cancer patients post-chemotherapy and radiation therapy.

Further, research is being conducted to develop cannabis-based drugs for the treatment of pain in illnesses such as epilepsy, anaemia and cancer by Council of Scientific and Industrial Research - Indian Institute of Integrative Medicine (CSIR - IIIM) in collaboration with Bombay Hemp Company (BOHECO), a startup which works with industrial hemp.

So, with such religious and historical connections to it, how can the consumption of marijuana be illegal in India?

The recreational usage of marijuana is illegal in India and is governed under the Narcotic Drugs and Psychotropic Substances Act, 1985. Consumption of marijuana is punishable with a jail term of six months or a fine of Rs 10,000, while illegal production and cultivation can be punished with a jail term of up to 10 years.

However, marijuana was legal in India until 1984. It was in the 1960s that the United States launched an offensive against the drug and a drive to ban it. During the 1961 Convention on Narcotics Drugs, India had even opposed the classification of marijuana as a hard drug.

Bucking under pressure, the Rajiv Gandhi administration passed the NDPS Act in 1985 which criminalised cannabis in its resin and bud form, but allowed the sale of bhang at government-approved shops.

Ironically, several states in the United States have now either legalised marijuana or are considering it. In India, various NGOs and activists have been asking for its legalisation. Their argument is that the criminalisation of marijuana has pushed the drug underground and to onto the hands of criminals who make it more potent and dangerous.

Story continues

Arguments favouringlegalising marijuana also say that it could lead to fewer chances of addiction. A study conducted in 1994 by epidemiologistJohn Anthony who surveyed more than 8,000 people about their marijuana usage, discovered that the chances of getting addicted to the drug were 9 per cent. For alcohol, this figure was 15 per cent, for heroin 23 per cent and for nicotine, 32 per cent.

Legalisation will also help villagersin areas like the Parbati Valley and the upper reaches of Kullu and Manali, and Idukki in Kerala whose main source of income comes from cannabis. Currently, with marijuana being illegal, farmers are forced to sell it to drug peddlers at low prices, and have problems with the police. Those for legalising the drug argue that by making the drug legally available, farmers would benefit from a more regulated market.

However, the fact remains that cannabis, when taken recreationally still remains a drug which could have harmful effects on the consumer. While a plant, it contains the mind-altering chemical, delta-9-tetrahydrocannabinol(THC), which is responsible for the intoxication that people who consume it feel.

The plant also has over 400 other chemicals. Researchers from the University of Alberta have identified potentially toxic chemicals in marijuana smoke which could have health effects. In a single puff of cannabis smoke, researchers have isolated around 110 toxic chemicals which may have carcinogenic, mutagenic or teratogenic effects, which could affect the development of the embryo or foetus.

Research conducted in Pittsburgh has also discovered that children of frequent marijuana users have relatively less attention span than their peers. Early marijuana usage has also been linked to a loss in I.Q levels of pre-teens.

Further, The Dunedin Multidisciplinary Health and Development Study conducted in Dunedin, New Zealand has found that people who smoke even one joint a week are prone to developing respiratory illnesses. Occasional smokers who cut down on weed, also had reduced symptoms, while heavy smokers had a persistent cough and wheeze even after cutting down, or quitting completely. This proves that the side effects of smoking weed on heavy smokers may linger for long.

Those who are against the legalisation of weed are also worried that its usage could prove to be a gateway to other, more potent, hard drugs.

Marijuana, if used responsibly, could help those cultivating it and using it. However, with India already grappling with problems of alcoholism, excessive tobacco usage, much more research needs to be carried out to ensure that the risks do not outweigh the potential benefits.

Visit link:
Hazy road to legalise marijuana: The case for it and risks involved - Yahoo Canada Shine On

Child Care of the Berkshires Inc.staff have returned to the office as of June 15.

The National Alliance on Mental Illness (NAMI) BerkshireCountyhas announced the addition of a Warm Line, 413-445-1136,a phone number that people can call to talk toeither a NAMI BC staff or a community trained volunteer having lived experience with mental health issues, trauma, and/or to assist individuals through a difficult time, such as the COVID-19 pandemic.NAMI Berkshire County will provide support over the phone as well as resources as available. Calls will be accepted during the day and evening until 8 p.m. Callers experiencing isolation, fear, stress can speak to someone so they will not feel as isolated and find some coping strategies that have worked for the operators staffing the phone.If operators are not available callers can leave their phone number and first name and they will be called back within 24 hours or sooner. The information is strictly confidential.

BHS Helpline.People should contact their primary care physician if theyhave concerns. Testing must be authorizedthroughthe primary care. TheBerkshire Health Systems helpline can answer many questions regarding findinga primary care, testing, or other health related issues.The Nurse Triage line has reduced its hours to 8 a.m. to 6 p.m. daily, still available seven days a week. The number remains 855-BMC-LINK, or 855-262-5465.

Northern Berkshire Adult Education has gone virtual!All classes are offered online, even the PCA class. Free to all adult learners. Brush up your skills to get your GED or to prepare to return to college from the comfort of your home. Contact Bob or AnnaMaria at 413-662-5330 or 413-662-5386.

nbCC Changes to Open Hours and Programs-The Northern Berkshire Community Coalition (nbCC), in an effort to help combat the spread of COVID-19, has made the following changes to open hours and programs:

More:
nbCC E-Zine - Oct. 1, 2020 - News and Events in Northern Berkshire - iBerkshires.com